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ABSTRACT
Objective To determine whether inclusion of glutamine,
selenium, or both in a standard isonitrogenous, isocaloric
preparation of parenteral nutrition influenced new
infections and mortality among critically ill patients.
Design Randomised, double blinded, factorial, controlled
trial.
Setting Level 2 and 3 (or combined) critical care units in
Scotland. All 22 units were invited, and 10 participated.
Participants 502 adults in intensive care units and high
dependency units for ≥48 hours, with gastrointestinal
failure and requiring parenteral nutrition.
Interventions Parenteral glutamine (20.2 g/day) or
selenium (500 μg/day), or both, for up to seven days.
Main outcome measures Primary outcomes were
participants with new infections in the first 14 days and
mortality. An intention to treat analysis and a prespecified
analysis of patients who received ≥5 days of the trial
intervention are presented. Secondary outcomes
included critical care unit and acute hospital lengths of
stay, days of antibiotic use, and modified SOFA (Sepsis-
related Organ Failure Assessment) score.
Results Selenium supplementation did not significantly
affect patients developing a new infection (126/251 v
139/251, odds ratio 0.81 (95% CI 0.57 to 1.15)), except
for those who had received ≥5 days of supplementation
(odds ratio 0.53 (0.30 to 0.93)). There was no overall
effect of glutamine on new infections (134/250 v 131/
252, odds ratio 1.07 (0.75 to 1.53)), even if patients
received ≥5 days of supplementation (odds ratio 0.99
(0.56 to 1.75)). Six month mortality was not significantly
different for selenium (107/251 v 114/251, odds ratio
0.89 (0.62 to 1.29)) or glutamine (115/250 v 106/252,
1.18 (0.82 to 1.70)). Length of stay, days of antibiotic use,
and modified SOFA score were not significantly affected
by selenium or glutamine supplementation.
Conclusions The primary (intention to treat) analysis
showed no effect on new infections or on mortality when
parenteral nutrition was supplemented with glutamine or
selenium. Patients who received parenteral nutrition
supplemented with selenium for ≥5 days did show a
reduction in new infections. This finding requires
confirmation.
Trial registration Current Controlled Trials
ISRCTN87144826
INTRODUCTION
Infection and sepsis aremajor causes of increasedmor-
tality, morbidity, and resource use in intensive care
units. They are associated with both illness and drug
related impairment of the immune system, com-
pounded by malnutrition often observed in patients
admitted to critical care.1
The enteral feeding route is preferred for critically ill
patients because of its reduced costs and risk of infec-
tive complications.2 Parenteral nutrition, however, has
an important role becausemany intensive care patients
have gastrointestinal dysfunction.3
Recent systematic reviews have suggested that par-
enteral administration of glutamine to critically ill
patients reduces mortality (risk ratio 0.71 (95% confi-
dence interval 0.55 to 0.92)) and new infections (risk
ratio 0.76 (0.62 to 0.93)).4 Selenium supplementation
in critical illness has also been shown to reducemortal-
ity (risk ratio 0.84 (0.67 to 1.05)) but with little effect on
infections (risk ratio 0.93 (0.70 to 1.23)).4 However,
these systematic reviews are based on small trials,
many of poor quality. These drawbacks, and concerns
that theremay be publication and reporting bias,mean
that large, well conducted randomised trials are still
required for definitive results.
We therefore conducted a large randomised con-
trolled trial examining whether the inclusion of gluta-
mine, selenium, or both in a standard isonitrogenous,
isocaloric preparation of parenteral nutrition influ-
enced the rate of new infections and mortality in criti-
cally ill patients.
METHODS
The full protocol for the trial is described elsewhere.5
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Setting
Department ofHealth level 2 and 3 intensive care units
ormixed adult units run by an intensivist were eligible.
All 22 Scottish intensive care units were invited to par-
ticipate, and 10 agreed. Scottish Intensive Care
Society’sAuditGroup’s (SICSAG)website and annual
report describe each site in detail (www.scottishintensi
vecare.org.uk/sicsag/annual%20report/index.htm).
Participants
Patients were eligible if they were expected to be on
intensive care and high dependency units for ≥48
hours, were aged ≥16 years, and required ≥50% of
their nutritional requirements to be met by parenteral
nutrition. Pregnant women and people whose
expected stay in the UKwas <6months were not eligi-
ble. Patients with estimated glomerular filtration rate
<10 ml/min and not receiving renal replacement ther-
apy were also excluded.
Design
We used a 2×2 factorial design67 to test whether gluta-
mine and selenium, either alone or in combination,
were effective. A remote telephone computer system
generated random allocation to one of four possible
groups with minimisation8 on trial centre, age (<65 or
≥65 years), sex, patient group (medical or surgical
(including trauma)), and nutritional status (undernour-
ished, normal, or obese by subjective clinical
assessment9). Patients, clinicians, and investigators
were blinded to treatment allocation. Consent proce-
dures followed the 2003 Mental Health (Care and
Treatment, Scotland) Act. Ethical approval was
obtained from the Multicentre Research Ethics Com-
mittee Scotland.
Interventions
The daily trial interventions were parenteral nutrition
bag containing (a) standard formulation (12.5 g nitro-
gen, 2000 kcal), (b) glutamine formulation (12.5 g nitro-
gen (including 20.2 g glutamine), 2000 kcal),
(c) standard formulation with addition of 500 μg sele-
nium, (d) glutamine formulation with addition of 500
μg selenium. Both standard and glutamine formula-
tions were tested for long term stability in parenteral
nutrition bags (1500 ml volume), and for short term
stability after addition of selenium. Selenium was
added by the hospital pharmacy aseptic unit. Standard
additions of fluid, electrolytes, vitamins, and minerals
(including low dose selenium, ≤50 μg daily) were
allowed. Additional parenteral nitrogen or energy
were not allowed to be added to the bags (to retain
the isonitrogenous nature of the interventions).
Trial intervention was for a maximum of seven days
(on critical care units and subsequently on hospital
wards). Trial parenteral nutrition was started as soon
as practicable with the pharmacy. For men weighing
<60 kg and women weighing <70 kg the volume
of feed could be reduced to reflect reduced
requirements.5
Measures of outcome
The primary outcomes were numbers of participants
with new infections in the first 14 days after randomisa-
tion and mortality (on critical care unit, and overall at
sixmonths). Infectionswere defined in twoways: (a) all
clinically suspected infections (primary definition) and
(b) only infections confirmed in accordance with the
Centers for Disease Control criteria (after review by
the adjudication committee).
Other outcome measures defined a priori were
length of stay on critical care unit, length of stay in
acute hospital, days of antibiotic use (assessed during
the 14 days after starting the trial intervention), modi-
fied Sequential Organ Failure Assessment (SOFA)
score assessed over seven days (central nervous system
domain removed as most patients were sedated in the
critical care units and some were admitted after head
injury), and serious adverse events for 14 days (exclud-
ing deaths). It was not possible to collect data on venti-
lator use.5
Quality of lifemeasures (SF-12 andEQ-5Dquestion-
naires) were collected at three and six months by post,
but will be presented in a separate paper with the eco-
nomic evaluation.
Information on deaths after discharge was obtained
from routine data collected by the Information Ser-
vices Division of the Scottish National Health Service.
Potential participants (n=1134)
Approached (n=575)
Randomised (n=502)
Excluded (n=559):
  Failed to meet inclusion criteria (n=506)
  Trial parenteral nutrition unavailable (n=53)
Consent not obtained (n=73)
Parenteral nutrition: With
glutamine
(n=126)
Received trial parenteral nutrition:
  ≥5 days
  <5 days
  None
* Percentages based on the number of participants alive at each time point
64 (51%)
59 (47%)
3 (2%)
With
selenium
(n=127)
51 (40%)
71 (56%)
5 (4%)
With
glutamine
+ selenium
(n=124)
60 (48%)
57 (46%)
7 (6%)
Total
(n=502)
230 (46%)
255 (51%)
17 (3%)
With
neither
(n=125)
55 (44%)
68 (54%)
2 (2%)
Alive at 3 months*:
  Completed questionnaire
  Did not complete
70
53 (76%)
17 (24%)
77
56 (73%)
21 (27%)
75
53 (71%)
22 (29%)
302
225 (75%)
77 (25%)
80
63 (79%)
17 (21%)
Died within 3 months 56 (44%) 50 (39%) 49 (40%) 200 (40%)45 (36%)
Alive at 6 months*:
  Completed questionnaire
  Did not complete
66
49 (74%)
17 (26%)
75
51 (68%)
24 (32%)
69
51 (74%)
18 (26%)
281
207 (74%)
74 (26%)
71
56 (79%)
15 (21%)
Died within 3-6 months 4 (3%) 2 (2%) 6 (5%) 21 (4%)9 (7%)
Fig 1 | Flow of patients through the trial
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Sample size and statistical analyses
The study was designed to detect a plausible reduction
of reported infections (with glutamine) within the first
14 days, a 15% reduction from 50% to 35%. About 340
patients would be required to detect this difference
(80% power, two sided 5% significance level). To
allow for loss of patients to follow-up during the six
months for other outcomes, the trial recruitment target
was inflated to 500 patients.
All outcomes were analysed on the basis of intention
to treat (that is, all participants analysed within the
group into which they were randomised irrespective
of subsequent compliance with nutritional support).
We also undertook a prespecified analysis of the pri-
mary outcomes in participants who received trial par-
enteral nutrition for at least five days.10
The principal comparisons were between (a) all
those randomised to glutamine formulation versus all
those not allocated glutamine and (b) all those rando-
mised to extra selenium versus all those not allocated
selenium. The primary outcome measures (infections
and mortality) were analysed using logistic regression.
Lengths of stay in the critical care or high dependency
unit and in acute hospital were analysed with Cox pro-
portional hazards models. Duration of treatment with
antibiotics and modified SOFA score were analysed
with the Mann-Whitney test.
All regressionmodels included covariates indicating
whether the patient had been allocated to receive glu-
tamine or selenium and the minimisation variables
(excluding trial centre). A two sided significance level
of 5% was considered evidence of statistical
significance, and corresponding confidence intervals
were calculated. An interaction between glutamine
and selenium was tested for by adding the interaction
term to the model (two sided 5% significance level).
Subgroup analyses, defined a priori, assessed sever-
ity of disease (Acute Physiology and Chronic Health
Evaluation II (APACHE II) scores split by median
score and the minimisation variables) by adding treat-
ment subgroup interaction terms to the models. We
used a two sided 1% significance level to test the treat-
ment by subgroup, interactions reflecting the more
speculative nature of these analyses.
RESULTS
A total of 1134 patients were screened for participation
from June 2004 to November 2008, of whom 506 did
not meet trial inclusion criteria (fig 1). For 53 patients,
trial parenteral nutrition was not immediately avail-
able, leaving 575 patients from whom consent was
sought. The 502 who were randomised were located
in 10 centres in Scotland.
Baseline characteristics
Baseline characteristics were well matched across
groups (table 1). Participants had a mean (SD) age of
63.8 (14.9) years, 39% were women, 89% required
level 3 care, 25% were medical patients (defined as
non-surgical cause for admission), and the median
APACHE II score was 20 (interquartile range 16–25).
At randomisation, 89% were already receiving anti-
biotics, and 27% were undernourished. The nature of
previous nutrition support was also well balanced
Table 1 | Baseline characteristics of 502 intensive care patients randomised to trial parenteral nutrition formulations. Values are numbers (percentages)
unless stated otherwise
Characteristic
Trial parenteral nutrition formulations
Individual formulations Combined groups
All
(n=502)
Glutamine
(n=126)
Selenium
(n=127)
Glutamine
+ selenium
(n=124)
Neither
(n=125)
Any
glutamine
(n=250)
Any non-
glutamine
(n=252)
Any selenium
(n=251)
Any non-
selenium
(n=251)
Mean (SD) age (years) 63.2 (14.5) 64.5 (14.2) 64.5 (15.7) 63.1 (15.3) 63.8 (15.1) 63.8 (14.7) 64.5 (14.9) 63.1 (14.8) 63.8 (14.9)
Female 49 (39) 50 (39) 49 (40) 50 (40) 98 (39) 100 (40) 99 (39) 99 (39) 198 (39)
Critical care unit level 3 114 (90) 116 (91) 108 (87) 109 (87) 222 (89) 225 (89) 224 (89) 223 (89) 447 (89)
Medical patient 30 (24) 30 (24) 36 (29) 31 (25) 66 (26) 61 (24) 66 (26) 61 (24) 127 (25)
APACHE II score: (n=126) (n=127) (n=122) (n=124) (n=248) (n=251) (n=249) (n=250) (n=499)
Median (IQR) 21 (16–26) 20 (15–25) 20 (16–24) 20 (16–25) 21 (16–25) 20 (15–25) 20 (16–25) 21 (16–25) 20 (16–25)
Sepsis 77/125 (62) 67/125 (54) 73/124 (59) 65/124 (52) 150/249 (60) 132/249 (53) 140/249 (56) 142/249 (57) 282/498 (57)
Nutritional status:
Underweight 35 (28) 36 (28) 32 (26) 34 (27) 67 (27) 70 (28) 68 (27) 69 (27) 137 (27)
Normal 69 (55) 69 (54) 71 (57) 72 (58) 140 (56) 141 (56) 140 (56) 141 (56) 281 (56)
Obese 22 (17) 22 (17) 21 (17) 19 (15) 43 (17) 41 (16) 43 (17) 41 (16) 84 (17)
Antibiotics used 114/125 (91) 113/126 (90) 105/124 (85) 114/124 (92) 219/249 (88) 227/250 (91) 218/250 (87) 228/249 (92) 446/499 (89)
Nutrition type: (n=125) (n=127) (n=124) (n=124) (n=249) (n=251) (n=251) (n=249) (n=500)
Enteral 28 (22) 21 (17) 27 (22) 23 (19) 55 (22) 44 (18) 48 (19) 51 (20) 99 (20)
Parenteral 42 (34) 44 (35) 45 (36) 42 (34) 87 (35) 86 (34) 89 (35) 84 (34) 173 (35)
Both 16 (13) 21 (17) 13 (10) 20 (16) 29 (12) 41 (16) 34 (14) 36 (14) 70 (14)
None 39 (31) 41 (32) 39 (31) 39 (31) 78 (31) 80 (32) 80 (32) 78 (31) 158 (32)
SD=standard deviation. IQR=interquartile range.
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between groups. Only 11 participants had already
received immune enhancing enteral or parenteral
nutrition, which was stopped before entering the trial
(see table A in appendix 1 on bmj.com). The median
time in critical care units before randomisation was
2.6 days.
Duration of trial parenteral nutrition use
The median duration of trial parenteral nutrition was
5.1 days for glutamine formulation only, 4.1 days for
standard formulation plus selenium, 5.0 days for gluta-
mine formulation plus selenium, and 4.7 days for stan-
dard formulation only.
Primary outcomes: new infections and mortality
New infections
Table 2 shows the results for the primary outcome
measures. Patients allocated to added selenium
showed a non-significant decrease in the rate of any
new infections in the next 14 days (126/251 (50%) for
selenium v 139/251 (55%) for no selenium, odds ratio
0.81 (95% confidence interval 0.57 to 1.15) P=0.24).
There was no evidence of any beneficial effect from
the glutamine formulation on new infections (134/
250 (54%) for glutamine v 131/252 (52%) for no gluta-
mine, odds ratio 1.07 (0.75 to 1.53) P=0.71). There was
no evidence of an interaction effect between glutamine
and selenium (odds ratio 0.98 (0.48 to 2.00) P=0.96).
The subgroupanalyses showedno statistically signif-
icant (1% level) interaction effects between the treat-
ments and the subgroups (fig 2).
When the definition of an infection was restricted to
the Centers for Disease Control criteria for confirmed
infections, results were similar to those for all new infec-
tions for selenium (104/251 (41%) for selenium v 121/
251 (48%) for no selenium, odds ratio 0.75 (0.52 to 1.08)
P=0.12) and for glutamine, which had a higher number
(118/250 (47%) for glutamine v 107/252 (42%) for no
glutamine, odds ratio 1.23 (0.86 to 1.76) P=0.27). There
was no statistical evidence of an interaction between
treatments (odds ratio 1.28 (0.62 to 2.64) P=0.50).
Mortality
Mortality within the critical care or high dependency
units was slightly higher with glutamine formulations
compared with standard formulations (88/250 (35%) v
Table 2 | Infection and mortality outcomes among 502 intensive care patients randomised to trial parenteral nutrition
formulations. Values are numbers (percentages) unless stated otherwise
Outcome
Trial parenteral nutrition formulations
Individual formulations Combined groups
Glutamine
(n=126)
Selenium
(n=127)
Glutamine
+ selenium
(n=124)
Neither
(n=125)
Any
glutamine
(n=250)
Any non-
glutamine
(n=252)
Any
selenium
(n=251)
Any non-
selenium
(n=251)
New infections*
All infections: 71 (56) 63 (50) 63 (51) 68 (54) 134 (54) 131 (52) 126 (50) 139 (55)
Odds ratio (95% CI) — — — — 1.07 (0.75 to 1.53) 0.81 (0.57 to 1.15)
Confirmed infections†: 62 (49) 48 (38) 56 (45) 59 (47) 118 (47) 107 (42) 104 (41) 121 (48)
Odds ratio (95% CI) — — — — 1.23 (0.86 to 1.76) 0.75 (0.52 to 1.08)
Mortality
Withincriticalcareorhigh
dependency unit:
46 (37) 42 (33) 42 (34) 38 (30) 88 (35) 80 (32) 84 (33) 84 (33)
Odds ratio (95% CI) — — — — 1.17 (0.80 to 1.71) 1.004 (0.69 to 1.47)
Within 6 months: 60 (48) 52 (41) 55 (44) 54 (43) 115 (46) 106 (42) 107 (43) 114 (45)
Odds ratio (95% CI) — — — — 1.18 (0.82 to 1.70) 0.89 (0.62 to 1.29)
*Within 14 days after randomisation.
†Confirmed in accordance with Centers for Disease Control definition.
All new infections within 14 days
Glutamine formulations:
  Nutritional status
  Patient type  
  Age (years)
  Sex
  APACHE II score 
Selenium formulations:
  Nutritional status
  Patient type  
  Age (years)
  Sex
  APACHE II score
 
Mortality at 6 months
Glutamine formulations:
  Nutritional status
  Patient type  
  Age (years)
  Sex
  APACHE II score 
Selenium formulations:
  Nutritional status
  Patient type  
  Age (years)
  Sex
  APACHE II score 
1.18 (0.41 to 3.37)
0.54 (0.18 to 1.62)
0.81 (0.32 to 2.11)
1.94 (0.74 to 5.08)
1.04 (0.48 to 2.25)
1.56 (0.54 to 4.45)
0.99 (0.33 to 3.00)
1.98 (0.76 to 5.17)
0.70 (0.26 to 1.84)
1.25 (0.57 to 2.71)
0.91 (0.31 to 2.64)
1.98 (0.64 to 6.14)
1.34 (0.50 to 3.57)
0.56 (0.21 to 1.50)
1.92 (0.86 to 4.26)
1.32 (0.45 to 3.84)
0.92 (0.29 to 2.85)
1.27 (0.47 to 3.40)
0.86 (0.32 to 2.32)
1.62 (0.73 to 3.64)
0.2 0.60.4 1 2 43 5
Subgroup
Normal/obese v undernourished
Medical v surgical
<65 v ≥65
Male v female
>20 v ≤20
Normal/obese v undernourished
Medical v surgical
<65 v ≥65
Male v female
>20 v ≤20
Normal/obese v undernourished
Medical v surgical
<65 v ≥65
Male v female
>20 v ≤20
Normal/obese v undernourished
Medical v surgical
<65 v ≥65
Male v female
>20 v ≤20
Comparisons Odds ratio
(95% CI)
Odds ratio
(95% CI)
Fig 2 | Subgroup analyses for infection and mortality outcomes among 502 intensive care
patients randomised to trial parenteral nutrition formulations
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80/252 (32%), odds ratio 1.17 (0.80 to 1.71) P=0.42),
but was unaffected by presence or absence of selenium
(84/251 (33%) v 84/251 (33%), odds ratio 1.004 (0.69 to
1.47) P=0.98) (table 2). The interaction term between
glutamine and selenium was also not significant (odds
ratio 0.77 (0.36 to 1.65) P=0.50).
Six month mortality was lower in the groups with
added selenium than in those without (107/251 (43%)
v 114/251 (45%), odds ratio 0.89 (0.62 to 1.29) P=0.54)
butwas higher in the groups given the glutamine formu-
lation than in those given standard formulation (115/
250 (46%) v 106/252 (42%), odds ratio 1.18 (0.82 to
1.70) P=0.38) (table 2). The interaction between gluta-
mine and selenium was not significant (odds ratio 0.95
(0.46 to 1.97) P=0.88). Figure 3 shows a plot of the
Kaplan-Meier survival estimates over the first six
months after randomisation for each treatment arm.
The subgroup analyses showed no significant inter-
action effects between the treatments and the sub-
groups (fig 2).
Further analyses
A priori analysis based on patients who had received a
minimum of five days of trial parenteral nutrition
showed that formulations with added selenium were
associated with a significantly reduced proportion of
participants with any new infection (odds ratio 0.53
(0.30 to 0.93) P=0.03), but the glutamine formulations
werenot (odds ratio0.99 (0.56 to1.75)P=0.96) (table 3).
These results were similar for confirmed infections.
For both mortality outcomes the effect sizes for both
glutamine and selenium were not statistically signifi-
cant (table 3).
The results for the primary outcomes were not
affected by a post hoc analysis adjusting for sepsis at
baseline (results not shown).
Other outcome measures
There was no evidence of a difference in length of stay,
modified SOFA score, or antibiotic use with trial inter-
ventions (table 4). Serious adverse events were similar
across the groups (10 cases each with the glutamine,
selenium, and glutamine plus selenium formulations,
and seven with the standard formulation only).
DISCUSSION
We assessed the effect of parenteral nutrition with glu-
tamine or selenium, or both, in a pragmatic, factorial,
rigorously designed randomised controlled trial in cri-
tically ill adults. Only the hospital research pharmacist
knew the treatment allocation but facilitated clinical
care by permitting individualisation of electrolyte,
vitamin, and mineral supplementation. This study
design achieved blinding of all data collection.11 The
manufacture and initiation of parenteral nutrition by
pharmacies did not differ from procedures outside
Time after randomisation (days)
Cu
m
ul
at
iv
e 
su
rv
iv
al
0 50 100 150 200
0
0.2
0.4
0.6
0.8
1.0
Glutamine + selenium
Neither
Glutamine
Formulation:
Selenium
Fig 3 | Kaplan-Meier survival plot over six months after
randomisation among 502 intensive care patients randomised
to trial parenteral nutrition formulations
Table 3 | Infection and mortality outcomes among 502 intensive care patients randomised to trial parenteral nutrition
formulations: restricted to those who received ≥5 days of trial formulation. Values are numbers (percentages) unless stated
otherwise
Outcome
Trial parenteral nutrition formulations
Individual formulations Combined groups
Glutamine
(n=126)
Selenium
(n=127)
Glutamine +
selenium
(n=124)
Neither
(n=125)
Any
glutamine
(n=250)
Any non-
glutamine
(n=252)
Any
selenium
(n=251)
Any non-
selenium
(n=251)
Received ≥5 days of trial
formulation
n=64 n=51 n=60 n=55 n=124 n=106 n=111 n=119
New infections*
All infections: 44 (69) 29 (57) 36 (60) 42 (76) 80 (65) 71 (67) 65 (59) 86 (72)
Odds ratio (95% CI) — — — — 0.99 (0.56 to 1.75) 0.53 (0.30 to 0.93)
Confirmed infections†: 38 (59) 23 (45) 32 (53) 39 (71) 70 (56) 62 (58) 55 (50) 77 (65)
Odds ratio (95% CI) — — — — 0.99(0.58 to 1.72) 0.52(0.30 to 0.90)
Mortality
Within critical care or
high dependency unit:
19 (30) 16 (31) 22 (37) 14 (25) 41 (33) 30 (28) 38 (34) 33 (28)
Odds ratio (95% CI) — — — — 1.20 (0.67 to 2.15) 1.40 (0.79 to 2.50)
Within 6 months: 28 (44) 18 (35) 27 (45) 24 (44) 55 (44) 42 (40) 45 (41) 52 (44)
Odds ratio (95% CI) — — — — 1.17 (0.68 to 2.02) 0.88 (0.51 to 1.52)
*Within 14 days after randomisation.
†Confirmed in accordance with Centers for Disease Control definition.
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the trial. This trial is the largest to date with a sample
size sufficient for rigorously testing our hypotheses.
Our primary analysis, on an intention to treat basis,
showed no evidence of benefit for selenium or gluta-
mine supplementation regarding a new infection.
However, when the analysis was restricted to partici-
pants who received at least five days of trial parenteral
nutrition there was a significant result in favour of sele-
nium. There was no statistical evidence of benefit with
regards to mortality.
Comparison with other studies and guidelines
Current guidance on nutrition support is available
from ASPEN1213 and ESPEN14 (American and Eur-
opean Societies of Parenteral and Enteral Nutrition)
and the Canadian critical care guidelines (updated
2009).4 ASPEN gives glutamine supplementation a
grade C evidence level and states: “When parenteral
nutrition is used in the critical care setting, considera-
tion should be given to supplementation with parent-
eral glutamine” at a dose of 0.5 g/kg/day.12 The
ESPEN guidelines concur with the Canadian guide-
lines (0.2–0.4 g/kg/day of L-glutamine).15 Our trial
provided glutamine supplementation within the
recommended dose range.
Clinical trials of selenium supplementation have
used a wide range of doses.16 In a systematic review
of antioxidant nutrients in critical illness, Heyland et
al found that selenium supplementation (alone or in
combination with other antioxidants) may be asso-
ciated with a reduction in mortality (relative risk 0.59
(95% confidence interval 0.32 to 1.08)).17 18
Strong biological arguments and clinical data indi-
cate that a minimum dose is needed for both supple-
ments before a “treatment effect” will occur.18 19
However, many patients die or move to enteral nutri-
tion support only a few days after starting parenteral
nutrition.We therefore included (on the recommenda-
tion of the Trial Steering Committee) the prespecified
analysis of patients who received at least five days of
trial intervention.
SIGNET represents a substantial and important
increase in evidence.4 20 When our data are added to
current meta-analyses for glutamine supplementation
the random effects risk ratio for mortality of 0.71 (95%
confidence interval 0.55 to 0.92) changes to 0.80 (0.62
to 1.04) (see fig A in appendix 2 on bmj.com), and the
risk ratio for new infection changes from 0.76 (0.62 to
0.93, I2=28%) to 0.81 (0.67 to 0.98, I2=43%) (fig B in
appendix 2). 4
Similarly, when our trial data for selenium supple-
mentation are entered into the current Cochrane sys-
tematic review21 the random effects risk ratio for
mortality changes from 0.75 (0.59 to 0.96, I2=0%) to
0.86 (0.74 to 1.00, I2=0%) (fig C in appendix 2), and
the risk ratio for new infections changes from 1.22
(0.67 to 2.23, I2=0%) to 0.93 (0.79 to 1.09, I2=0%) (fig
D in appendix 2).
Strengths and limitations of study
Comprehensive national audit data for outcomes from
Scottish critical care are publicly available (www.sic
sag.scot.nhs.uk/), and, despite some variation between
unit performances, an international audit of guideline
compliance (Canadian Critical Care Nutrition Group)
in 2007 and 2008 showed Scottish intensive care units
compared favourably with intensive care units from
around the world. These data indicate that SIGNET
has strong external validity and generalisability of
results.
The general methodological quality of a clinical trial
can be gauged from three criteria: concealment of ran-
dom treatment allocation, appropriate implementa-
tion of blinding, and presentation of an intention to
Table 4 | Length of hospital stay, length of antibiotic treatment, and modified SOFA score among 502 intensive care patients randomised to trial parenteral
nutrition formulations: intention to treat analysis. Values are medians (interquartile ranges) unless stated otherwise
Outcome
Trial parenteral nutrition formulations
Individual formulations Combined groups
Glutamine
(n=126)
Selenium
(n=127)
Glutamine +
selenium
(n=124) Neither (n=125)
Any glutamine
(n=250)
Any non-
glutamine
(n=252)
Any selenium
(n=251)
Any non-
selenium
(n=251)
Length of stay (days):
In critical care or high
dependency unit:
16.4 (8.1–29.8) 12.9 (7.8–23.9) 14.4 (7.8–23.6) 14.6 (8.4–24.9) 15.0 (7.9–28.4) 13.4 (8.2–23.9) 13.2 (7.8–23.7) 15.1 (8.3–28.4)
Hazard ratio (95% CI) — — — — 0.96 (0.80 to 1.14) 1.08 (0.91 to 1.29)
In acute hospital: 33.8 (14.7–58.1) 28.3 (14.7–50.3) 31.2 (14.6–53.4) 27.3 (15.2–52.9) 32.5 (14.7–55.6) 28.2 (15.1–52.4) 29.8 (14.7–52.4) 31.2 (15.1–57.8)
Hazard ratio (95% CI) — — — — 0.89 (0.75 to 1.06) 1.05 (0.88 to 1.26)
Days of antibiotic use: 2 (0–11) 0 (0–8) 0 (0–14.5) 0 (0–8) 0 (0–14) 0 (0–8) 0 (0–10) 0 (0–10)
Mann-Whitney z score
(P value)
— — — — –1.69 (0.09) –0.80 (0.42)
Modified SOFA score over one
week*:
(n=72) (n=62) (n=71) (n=64) (n=143) (n=126) (n=133) (n=136)
Score 4 (3–8) 5 (3–8) 5 (3–8) 4 (3–7.5) 5 (3–8) 4 (3–8) 5 (3–8) 4 (3–8)
Mann-Whitney z score
(P value)
— — — — –0.65 (0.51) –0.74 (0.46)
*Modified SOFA (Sequential Organ Failure Assessment) score was calculated as the sum of five of the six standard components; the central nervous system component not having been
collected.
RESEARCH
page 6 of 8 BMJ | ONLINE FIRST | bmj.com
treat analysis. Despite a CONSORT statement in
1996,22 nutritional support studies are noted to be sig-
nificantly poorer than sepsis trials in all aspects of
methodological quality.23 However, SIGNET has con-
siderable methodological strengths, including its fac-
torial design.6 7
As in many parts of the world, nutritional support in
the United Kingdom is not individualised for each
patient to the exact protein and calorie requirement
calculated from basal metabolic rate and allowing for
activity or sepsis. The SIGNET parenteral nutrition
formulation was designed to meet average estimated
requirements for most patients. To avoid overfeeding
patients with lower requirements, there was the facility
to reduce the total amount infused. At the time of study
design, the National Institute for Health and Clinical
Excellence (NICE) concluded there was no evidence
of improved outcomes from trying to tailor require-
ments accurately. This is a potential limitation of the
findings of this study for critical care units that use these
alternative approaches. Nevertheless, all groups were
equally affected by this nutrition approach, which
reflects clinical practice in most critical care units.
Patients’ height and weight (actual or estimated)
were collected in the trial. These data show that the
dose of glutamine (about 0.25 g glutamine/kg body
weight for men and 0.3 g/kg for women) was in keep-
ing with contemporary guidelines on nutritional
support.15 There may have been a small variation in
the dose, but there was no signal within the results sug-
gesting benefit from glutamine supplementation.
Nutritional assessment in critical care varies from
the optimal24 to pragmatic bedside clinical assessment.
As this was a pragmatic trial, we used a validated bed-
side screening tool, which reflects current practice in
the UK.
The SIGNET trial followed routine clinical prac-
tices, so that its results would be generalisable. Thus,
parenteral nutrition was provided based on clinical
need and was made available as soon as practicable
after the decision to start it, almost always within 24
hours. There was no prespecified time to start parent-
eral nutrition after admission to the critical care unit
given the lack of evidence or consensus as to the best
time to start parenteral nutrition. Many patients had
already developed severe sepsis or septic shock and
had established gastrointestinal failure as part of multi-
ple organ failure before the decision to start parenteral
nutrition. It is arguable whether earlier administration
of either trial supplement might offer benefit in terms
of supporting host defences. However, accurate pre-
diction of multiple organ failure in hospital patients is
not usually possible.
New infections were recorded for only the first
14 days. The intervention was set to a maximum of
seven days, based on previous trial evidence, and it
was considered that a longer lasting effect of the trial
intervention was unlikely to be evident.
SIGNET is the largest and highest quality trial of
parenteral nutrition conducted to date. It is pragmatic
in design,with patient centred outcomes. The results of
this trial were not expected, and they will energise con-
siderable debate. The glutamine data are contrary to
the beliefs of many clinicians that there is a conditional
deficiency of glutamine in critical illness (an unproved
construct) and that glutamine supplementation is ben-
eficial.
Selenium is inexpensive, simple to deliver, and at the
dose tested in SIGNEThas low toxicity. If the explora-
tory results presented here were confirmed, it would
provide a cost effective intervention in critically ill
patients.
Conclusion
Theremay be a benefit from supplementing parenteral
nutrition administered during critical illness with
500 μg of selenium daily for at least five days, in
terms of risk of new infection. There was no evidence
of benefit with glutamine supplementation. Future
research should confirm or refute the finding of benefit
with five days of selenium supplementation.
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